NervGen Pharma

NervGen Pharma EBIT

The EBIT of NervGen Pharma (NGEN.V) as of Oct 27, 2026 is -25.08 M CAD. In the previous year, EBIT was -24.92 M CAD — a change of 0.66% (lower).

EBIT

-25.08 MCAD

YoY

0.66%

Last updated:

In 2025, NervGen Pharma's EBIT was -25.08 M CAD, a 0.66% increase from the -24.92 M CAD EBIT recorded in the previous year.

The NervGen Pharma EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2023
-17.78 M CAD
Jan 1, 2024
-24.92 M CAD
Jan 1, 2025
-25.08 M CAD
Jan 1, 2026 (e)
0.00 CAD
Jan 1, 2027 (e)
0.00 CAD
Jan 1, 2028 (e)
0.00 CAD
Jan 1, 2029 (e)
467.76 M CAD
Jan 1, 2030 (e)
700.55 M CAD
The NervGen Pharma EBIT history
YEAREBITYoY
est700.55 MCAD+49.77%
est467.76 MCAD—
est0.00CAD—
est0.00CAD—
est0.00CAD-100.00%
-25.08 MCAD+0.66%
-24.92 MCAD+40.14%
-17.78 MCAD-22.10%
-22.82 MCAD+76.80%
-12.91 MCAD+15.04%
-11.22 MCAD+10.73%
-10.13 MCAD+648.31%
-1.35 MCAD+11,198.93%
-11,985.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NervGen Pharma Revenue

NervGen Pharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
0.00 CAD
-17.78 M CAD
-22.38 M CAD
Jan 1, 2024
0.00 CAD
-24.92 M CAD
-23.99 M CAD
Jan 1, 2025
0.00 CAD
-25.08 M CAD
-44.12 M CAD
Jan 1, 2026 (e)
0.00 CAD
0.00 CAD
-20.90 M CAD
Jan 1, 2027 (e)
0.00 CAD
0.00 CAD
-16.24 M CAD
Jan 1, 2028 (e)
13.73 M CAD
0.00 CAD
803,819.54 CAD
Jan 1, 2029 (e)
175.76 M CAD
467.76 M CAD
158.12 M CAD
Jan 1, 2030 (e)
615.15 M CAD
700.55 M CAD
351.73 M CAD

NervGen Pharma Margins

NervGen Pharma stock margins

The NervGen Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of NervGen Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for NervGen Pharma.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
0.00 %
- %
- %
Jan 1, 2024
0.00 %
- %
- %
Jan 1, 2025
0.00 %
- %
- %
Jan 1, 2026 (e)
0.00 %
0.00 %
- %
Jan 1, 2027 (e)
0.00 %
0.00 %
- %
Jan 1, 2028 (e)
0.00 %
0.00 %
5.86 %
Jan 1, 2029 (e)
0.00 %
266.14 %
89.96 %
Jan 1, 2030 (e)
0.00 %
113.88 %
57.18 %

NervGen Pharma Stock analysis

What does NervGen Pharma do? NervGen Pharma Corp. develops therapeutics for nerve damage, focusing on spinal cord injuries, peripheral nerve injuries, Alzheimer’s disease, and multiple sclerosis. The company advances its lead compound NVG-291, a therapeutic peptide mimicking the intracellular domain of protein tyrosine phosphatase, targeting chondroitin sulfate proteoglycans to regulate neuroplasticity and central nervous system repair. NervGen US Inc. and NervGen Australia Pty Ltd. are its wholly owned subsidiaries supporting global development efforts. The company generates revenue through the discovery, development, and commercialization of pharmaceutical products, with NVG-291 as the primary focus for clinical advancement and potential future sales. NervGen Pharma Corp. targets medical professionals and healthcare institutions seeking treatments for nervous system damage caused by injury or disease. The firm’s products, including NVG-291, are designed for therapeutic use in spinal cord injury, Alzheimer’s disease, and multiple sclerosis, with commercialization efforts centered on clinical trials and regulatory approvals. The company’s business model relies on advancing NVG-291 through development stages to secure market entry and eventual product sales, leveraging its subsidiaries for international operations. The company’s revenue streams are derived from the discovery, development, and commercialization phases of its pharmaceutical products. NVG-291 serves as the flagship therapeutic, with potential applications across multiple neurological conditions. NervGen US Inc. and NervGen Australia Pty Ltd. facilitate global market access and regulatory compliance, supporting the transition from research to commercial product availability. NervGen Pharma is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing NervGen Pharma's EBIT

NervGen Pharma's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of NervGen Pharma's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

NervGen Pharma's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in NervGen Pharma’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about NervGen Pharma stock

EBIT of NervGen Pharma is -25.08 M CAD in 2025.

EBIT of NervGen Pharma changed from -24.92 M CAD to -25.08 M CAD, representing a 0.66% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT NervGen Pharma since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's NervGen Pharma historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — NervGen Pharma

All Key Metrics — NervGen Pharma